Shares of HCW Biologics Inc. (NASDAQ:HCWB – Get Free Report) shot up 1.2% during trading on Tuesday . The company traded as high as $0.44 and last traded at $0.41. 226,408 shares were traded during trading, a decline of 2% from the average session volume of 230,527 shares. The stock had previously closed at $0.41.
HCW Biologics Stock Performance
The firm’s 50 day moving average price is $0.47 and its two-hundred day moving average price is $0.53. The firm has a market cap of $15.13 million, a PE ratio of -0.40 and a beta of 0.87. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.07 and a current ratio of 0.07.
About HCW Biologics
HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.
Read More
- Five stocks we like better than HCW Biologics
- Quiet Period Expirations Explained
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- How to Short a Stock in 5 Easy Steps
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
